Linmiao Jiang

8PUBLICATIONS
53CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersEpigenetics (incl. genome methylation and epigenomics)Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jul 14, 2026
Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial.

|Nov 03, 2025
Noninvasive genotyping and early disease dynamics demonstrate the efficacy of ibrutinib in combination with immunochemotherapy in patients with mantle cell lymphoma treated in the TRIANGLE trial.

Mouhamad Khouja, Elisa Genuardi, Simone Ferrero

|Oct 23, 2024
Conditional survival of younger patients with mantle cell lymphoma: Results from a randomized phase III trial of the European MCL Network.

Linmiao Jiang, Martin Dreyling, Olivier Hermine

|Sep 16, 2024
Comprehensive genetic analysis by targeted sequencing identifies risk factors and predicts patient outcome in Mantle Cell Lymphoma: results from the EU-MCL network trials.

Mouhamad Khouja, Linmiao Jiang, Karol Pal

|Apr 27, 2024
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network.

Luca Fischer, Linmiao Jiang, Jan Dürig

|Nov 22, 2023
Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results From the European Mantle Cell Lymphoma Elderly Trial.

Eva Hoster, Marie-Hélène Delfau-Larue, Elizabeth Macintyre

Pageof 2

Frequent Collaborators

8 joint publications

Eva Hoster

5 joint publications

Christiane Pott

3 joint publications

Martin Dreyling

2 joint publications

Stefan Wirths